ZHANG Wei 1,2 , LIU Fan 1,2 , SONG Ailin 1,2 , ZHOU Yanming 1,3
  • 1. The Second Clinical Medical College, Lanzhou University, Lanzhou 730030, P. R. China;
  • 2. Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou 730030, P. R. China;
  • 3. Department of Hepatobiliary and Pancreatic Vascular Surgery, The First Affiliated Hospital of Xiamen University, Xiamen 361003, P. R. China;
ZHOU Yanming, Email: zhouymsxy@sina.cn
advanced colorectal cancer; microsatellite instability-high; defective mismatch repair; programmed death-1
10.7507/1007-9424.202403085
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To understand the effect of programmed death-1 (PD-1) inhibitors on defective mismatch repair (dMMR) / microsatellite instability-high (MSI-H) advanced colorectal cancer (CRC). Method The literature of recent research relevant PD-1 inhibitors in the utility for patients with dMMR/MSI-H advanced CRC was reviewed and summarized. Results At present, there were many studies exploring the utility of anti-PD-1 inhibitors for the treatment of dMMR/MSI-H advanced CRC (including locally advanced CRC and metastatic CRC), and some studies were still in trials. Studies had consistently shown that the use of PD-1 inhibitors in dMMR/MSI-H advanced CRC as first-line or subsequent therapy, as well as in the neoadjuvant setting, leading to significant survival benefits. These benefits were particularly notable in cases of dMMR/MSI-H metastatic CRC with concurrent BRAF/RAS mutations and in the context of neoadjuvant immunotherapy aimed at organ preservation in locally advanced dMMR/MSI-H CRC. Moreover, there were numerous studies exploring “dual immunotherapy”, and most studies found that its efficacy was superior to that of single immunotherapy. However, the more adverse events were reported by the “dual immunotherapy” compared to the single immunotherapy. Conclusions Overall, based on results of the literature reviewed, PD-1 inhibitors have shown significant clinical benefits in dMMR/MSI-H advanced CRC, but there are still more issues that need to be further explored, such as discovering more first-line PD-1 inhibitors, overcoming drug resistance and adverse events. Future clinical practice should prioritize more precise individualized identification and the application of more effective combination therapy regimens to further optimize outcomes for patients with dMMR/MSI-H advanced CRC.

Citation： ZHANG Wei, LIU Fan, SONG Ailin, ZHOU Yanming. Advances in programmed death-1 inhibitors for advanced colorectal cancer with defective mismatch repair / microsatellite instability-high. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(8): 998-1004. doi: 10.7507/1007-9424.202403085 Copy

  • Previous Article

    Advances in the study of morphological evaluation of the landing zone and clinical outcomes in endovascular aortic aneurysm repair